Skip to main content

Table 4 Adverse events occurring during adjuvant chemotherapy

From: Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study

Characteristics

NSA group, n = 218

SA group, n = 232

P-value

Any grade

Grade 3/4

Any grade

Grade 3/4

 

Nausea/vomiting

64 (29.4)

13 (6.0)

57 (24.6)

20 (8.6)

a0.252; b0.280

Diarrhea

21 (9.6)

4 (1.8)

30 (12.9)

7 (3.0)

a0.270; b0.546

Constipation

16 (7.3)

1 (0.5)

21 (9.1)

2 (0.9)

a0.509; b1.000

Anemia

84 (38.5)

21 (9.6)

58 (25.0)

30 (12.9)

a0.002; b0.300

Leukopenia/neutropenia

102 (46.8)

29 (13.3)

72 (31.0)

34 (14.7)

a0.001; b0.679

Thrombocytopenia

42 (19.3)

11 (5.0)

38 (16.4)

14 (6.0)

a0.423; b0.647

Allergy

26 (11.9)

3 (1.4)

34 (14.7)

3 (1.3)

a0.395; b1.000

Hand-foot syndrome

19 (8.7)

6 (2.8)

10 (4.3)

4 (1.7)

a0.057; b0.533

Liver dysfunction

14 (6.4)

3 (1.4)

18 (7.8)

7 (3.0)

a0.581; b0.341

Fever

21 (9.6)

6 (2.8)

19 (8.2)

5 (2.2)

a0.591; b0.682

Urinary tract infection

9 (4.1)

3 (1.4)

11 (4.7)

2 (0.9)

a0.753; b0.677

  1. Values are presented as number (%). NSA: neoadjuvant chemotherapy plus surgery plus adjuvant chemotherapy; SA: surgery plus adjuvant chemotherapy. a for the statistic difference of any grade adverse events between the two groups. b for the statistic difference of grade 3/4 adverse events between the two groups